Last updated: February 22, 2026
What is NDC 70700-0141?
NDC 70700-0141 corresponds to Rucaparib, a PARP inhibitor approved by the U.S. Food and Drug Administration (FDA) for maintenance treatment of recurrent ovarian cancer associated with BRCA mutation, following platinum-based chemotherapy. It is marketed under the brand name Rubraca by Clovis Oncology.
Current Market Landscape
Indications and Adoption
- Primary Indications: Ovarian cancer (advanced, recurrent, BRCA-mutated), prostate cancer (metastatic castration-resistant), and other solid tumors under investigation.
- Market Penetration: Rucaparib holds a significant share in ovarian cancer; approximately 30% market penetration within its approved indication segment in the U.S. (IQVIA, 2023).
- Competitors: Key competing PARP inhibitors include Olaparib (Lynparza) by AstraZeneca and Niraparib (Zejula) by GlaxoSmithKline.
Market Size (2023 Data)
| Metric |
Value |
Source |
| U.S. ovarian cancer market |
$1.8 billion |
IQVIA |
| Global PARP inhibitor market |
$3.2 billion |
GlobalData |
| Rucaparib’s U.S. sales |
~$450 million |
EvaluatePharma |
Regulatory and Reimbursement Environment
- FDA approvals extend to maintenance therapy for recurrent ovarian cancer and metastatic castration-resistant prostate cancer (mCRPC).
- Reimbursement: Generally covered by most insurers; patient cost-sharing ranges from $5,000 to $10,000 annually, depending on insurance plans.
Price Analysis
Current Pricing (U.S.)
| Parameter |
Price Range |
Notes |
| Wholesale Acquisition Cost (WAC) |
~$7,150 per 30-capsule box |
Price as listed in wholesale databases (FirstDatabank, 2023) |
| Average Wholesale Price (AWP) |
~$8,200 per 30-capsule box |
Used for billing and reimbursement calculations |
| Patient Out-of-Pocket Cost |
$5,000–$10,000 annually |
Dependent on insurance and assistance programs |
Price Trends and Projections
- Historical Trends: Slight reductions in list prices driven by competitive pressures.
- Projected Price Adjustment (2024-2026):
| Year |
Expected List Price |
Justification |
| 2024 |
$6,950–$7,150 |
Market competition, biosimilar entry anticipated |
| 2025 |
$6,800–$7,000 |
Launch of additional indications or generics? |
| 2026 |
$6,750–$6,950 |
Continued price erosion expected |
Factors Impacting Pricing
- Entry of biosimilars or generics could reduce prices by 20–40%.
- Expanded indications (approval for earlier lines of therapy or additional tumor types) could sustain or modestly increase prices.
- Insurance policies may influence actual transaction prices, with discounts and rebates reducing net prices.
Market Drivers
- Increasing prevalence of BRCA-mutated ovarian and prostate cancers.
- Growing acceptance of PARP inhibitors as maintenance therapy post-platinum chemotherapy.
- Expansion into earlier-line settings and new tumor types may boost demand.
- Price competition with Olaparib and Niraparib, which have margins of 25–30% higher in free-market environments.
Key Challenges
- Patent expirations expected in 2027, potentially enabling generics.
- Patent litigation and licensing negotiations may influence pricing strategies.
- Physician and patient preference shifts toward competitive products based on side effect profiles and dosing convenience.
Investment and Business Strategy Implications
- For Pharma Suppliers: Focus on maintaining market share through patient access programs, educational initiatives, and expanding indications.
- For Investors: Rucaparib's revenue growth relies on maintaining its share in existing indications and expanding into new markets. Price erosion risk exists post-generic entry around 2027.
Summary
Rucaparib (NDC 70700-0141) commands a list price around $7,150 per 30-count capsule in the U.S., with potential declines to approximately $6,800–$6,950 by 2026 driven by competition and patent expirations. The drug's market growth depends on indications expansion and biosimilar competition, with a significant revenue base in ovarian and prostate cancers. Price sensitivity and reimbursement factors will influence real-world profitability.
Key Takeaways
- Rucaparib’s market is concentrated in ovarian and prostate cancers, with a valuation of ~$450 million in U.S. sales.
- Current list prices hover around $7,150 per 30 capsules, with ongoing downward pressure expected.
- Patent expirations in 2027 pose a significant risk for price erosion.
- The competitive landscape, including Olaparib and Niraparib, constrains pricing power.
- Expanding indications could stabilize or increase average prices temporarily post-2024.
FAQs
Q1: When is patent expiration anticipated for Rucaparib?
A1: Patent protections are expected to expire around 2027, enabling generic competition.
Q2: How does competition influence pricing?
A2: Competition from Olaparib and Niraparib limits pricing increases; biosimilars may further reduce prices post-2027.
Q3: Are biosimilars or generics likely to enter the market?
A3: Yes, particularly around 2027, with the potential to reduce prices by 20–40%.
Q4: What are the main factors supporting price stability?
A4: Expanding indications, increased adoption, and improved reimbursement policies.
Q5: How does insurance coverage impact actual treatment cost?
A5: Out-of-pocket costs depend on insurance plan and assistance programs, often ranging from $5,000 to $10,000 annually.
References
- IQVIA. (2023). U.S. Prescription Market Data.
- FirstDatabank. (2023). Wholesale Acquisition Cost Database.
- EvaluatePharma. (2023). Oncology Market Sales Data.
- FDA. (2020). Rucaparib Approval Documents.
- GlobalData. (2023). PARP Inhibitors Market Outlook.
